• Multi-arm randomized trial
• Pre-intensive care unit (ICU) COVID-19 patients
• Immunomodulatory drug EDP1815 vs. dapagliflozin + ambrisentan vs. standard care
• Primary outcome includes need for cardiovascular organ support